Accès ouvert
2021
article
OpenAlex
Maureen G. Maguire, Danni Liu, Susan B. Bressler, Scott M. Friedman et autres
IMPORTANCE: The follow-up schedule for individuals with eyes treated with anti-vascular endothelial growth factor agents for proliferative diabetic retinopathy (PDR) requires that patients return frequently for monitoring and repeated treatment. The likelihood that a patient will comply should be a consideration in …
us
(code pays fourni par la source)
2018
article
OpenAlex
Michael A. Grassi, Manvi P. Maker, Michael F. Marmor
us
(code pays fourni par la source)
Accès ouvert
2015
article
OpenAlex
Scott M. Friedman, Talat Almukhtar, Carl W. Baker, Adam R. Glassman et autres
PURPOSE: To evaluate the effect of a topical, nonsteroidal antiinflammatory drug, nepafenac 0.1%, in eyes with noncentral diabetic macular edema. METHODS: Multicenter, double-masked randomized trial. Individuals with good visual acuity and noncentral-involved diabetic macular edema were randomly assigned to nepafenac 0.1% (N …
us
(code pays fourni par la source)
2012
article
OpenAlex
Manvi P. Maker, Jason A. Noble, Paolo S. Silva, Jerry D. Cavallerano et autres
BACKGROUND: Early Treatment Diabetic Retinopathy Study (ETDRS) seven-standard-field color stereoscopic retinal photography (ETDRS photos) has been a gold standard for determining diabetic retinopathy (DR) severity. The Automated Retinal Imaging System (ARIS™, model 110, Visual Pathways, Inc., Prescott, AZ) acquires seven-sequential color stereoscopic …
us
(code pays fourni par la source)